Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07215559 · ClinicalTrials.gov registry record · Phase 2
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
A Phase 2 study of Obesity and Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT07215559 is a Phase 2 study of Obesity and Diabetes Mellitus, Type 2 that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 200 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT07215559, a Phase 2 study of Obesity and Diabetes Mellitus, Type 2, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.
Conditions Studied
Interventions
- DRUG Eloralintide
- DRUG Macupatide
- DRUG Macupatide Placebo
- DRUG Eloralintide Placebo
Study Locations (20)
Texas
- Mercy Family Clinic - Dallas
- Velocity Clinical Research, Dallas - Dallas
- PlanIt Research, PLLC - Houston
- Aavon Clinical Trials - Richmond
- Consano Clinical Research, LLC - Shavano Park
- Texas Valley Clinical Research - Weslaco
Georgia
- SKY Clinical Research Network Group-Brown - Atlanta
- Teak Research Consults - Lawrenceville
- AGILE Clinical Research Trials, LLC - Sandy Springs
- Pivotal Research Solutions - Stonecrest
- Rophe Adult and Pediatric Medicine/SKYCRNG - Union City
Arizona
- Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC - Gilbert
- Synexus Clinical Research US, Inc. - Phoenix
- Pima Heart - Tucson
Virginia
- Eastern Virginia Medical School (EVMS) Medical Group - Norfolk
- Clinical Research Partners, LLC - Richmond
Nevada
- Vector Clinical Trials - Las Vegas
New Jersey
- Premier Research - Trenton
Utah
- Kalo Clinical Research - West Valley City
Washington
- Northwest Clinical Research Center - Bellevue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-10-16 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07215559
The ClinicalTrials.gov registry entry for NCT07215559 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (76% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Eloralintide is the first listed.
NCT07215559 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Texas, Georgia, Arizona.
Frequently Asked Questions
What is clinical trial NCT07215559 about?
NCT07215559 is a clinical study titled "A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes". The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.
What is the current status of trial NCT07215559?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-10-16. Estimated completion is 2027-05.
What conditions does trial NCT07215559 study?
This clinical trial studies the following conditions: Obesity, Diabetes Mellitus, Type 2, Overweight.
What interventions are being tested in trial NCT07215559?
The interventions under investigation include: Eloralintide (DRUG), Macupatide (DRUG), Macupatide Placebo (DRUG), Eloralintide Placebo (DRUG).
Who is sponsoring clinical trial NCT07215559?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07215559 being conducted?
This trial has 20 study locations across Arizona, Georgia, Nevada, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.